vs
艾诺斯（ENS）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
艾诺斯的季度营收约是Revvity的1.2倍（$919.1M vs $772.1M），Revvity净利率更高（12.7% vs 9.8%，领先2.9%），Revvity同比增速更快（5.9% vs 1.4%），艾诺斯自由现金流更多（$171.3M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 0.5%）
艾诺斯是全球领先的工业储能系统及技术供应商，主营备用电源、动力电源类电池的生产，同时还提供电池充电器、电力设备、电池配件及户外设备防护机箱等相关产品，可充分满足各类工业场景的储能需求。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ENS vs RVTY — 直观对比
营收规模更大
ENS
是对方的1.2倍
$772.1M
营收增速更快
RVTY
高出4.4%
1.4%
净利率更高
RVTY
高出2.9%
9.8%
自由现金流更多
ENS
多$9.5M
$161.8M
两年增速更快
RVTY
近两年复合增速
0.5%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $919.1M | $772.1M |
| 净利润 | $90.4M | $98.4M |
| 毛利率 | 30.1% | — |
| 营业利润率 | 13.5% | 14.5% |
| 净利率 | 9.8% | 12.7% |
| 营收同比 | 1.4% | 5.9% |
| 净利润同比 | -21.3% | 3.9% |
| 每股收益（稀释后） | $2.40 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ENSRVTY
| Q4 25 | $919.1M | $772.1M | ||
| Q3 25 | $951.3M | $698.9M | ||
| Q2 25 | $893.0M | $720.3M | ||
| Q1 25 | $974.8M | $664.8M | ||
| Q4 24 | $906.2M | $729.4M | ||
| Q3 24 | $883.7M | $684.0M | ||
| Q2 24 | $852.9M | $691.7M | ||
| Q1 24 | $910.7M | $649.9M |
净利润ENSRVTY
| Q4 25 | $90.4M | $98.4M | ||
| Q3 25 | $68.4M | $46.7M | ||
| Q2 25 | $57.5M | $53.9M | ||
| Q1 25 | $96.5M | $42.2M | ||
| Q4 24 | $114.8M | $94.6M | ||
| Q3 24 | $82.3M | $94.4M | ||
| Q2 24 | $70.1M | $55.4M | ||
| Q1 24 | $60.9M | $26.0M |
毛利率ENSRVTY
| Q4 25 | 30.1% | — | ||
| Q3 25 | 29.1% | 53.6% | ||
| Q2 25 | 28.4% | 54.5% | ||
| Q1 25 | 31.2% | 56.5% | ||
| Q4 24 | 32.9% | — | ||
| Q3 24 | 28.5% | 56.3% | ||
| Q2 24 | 27.9% | 55.7% | ||
| Q1 24 | 27.9% | 54.6% |
营业利润率ENSRVTY
| Q4 25 | 13.5% | 14.5% | ||
| Q3 25 | 9.7% | 11.7% | ||
| Q2 25 | 9.7% | 12.6% | ||
| Q1 25 | 13.5% | 10.9% | ||
| Q4 24 | 15.7% | 16.3% | ||
| Q3 24 | 11.2% | 14.3% | ||
| Q2 24 | 10.7% | 12.4% | ||
| Q1 24 | 8.9% | 6.8% |
净利率ENSRVTY
| Q4 25 | 9.8% | 12.7% | ||
| Q3 25 | 7.2% | 6.7% | ||
| Q2 25 | 6.4% | 7.5% | ||
| Q1 25 | 9.9% | 6.4% | ||
| Q4 24 | 12.7% | 13.0% | ||
| Q3 24 | 9.3% | 13.8% | ||
| Q2 24 | 8.2% | 8.0% | ||
| Q1 24 | 6.7% | 4.0% |
每股收益（稀释后）ENSRVTY
| Q4 25 | $2.40 | $0.86 | ||
| Q3 25 | $1.80 | $0.40 | ||
| Q2 25 | $1.46 | $0.46 | ||
| Q1 25 | $2.39 | $0.35 | ||
| Q4 24 | $2.88 | $0.77 | ||
| Q3 24 | $2.01 | $0.77 | ||
| Q2 24 | $1.71 | $0.45 | ||
| Q1 24 | $1.48 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $450.1M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.9B | $7.3B |
| 总资产 | $4.0B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ENSRVTY
| Q4 25 | $450.1M | $919.9M | ||
| Q3 25 | $388.6M | $931.4M | ||
| Q2 25 | $346.7M | $991.8M | ||
| Q1 25 | $343.1M | $1.1B | ||
| Q4 24 | $463.2M | $1.2B | ||
| Q3 24 | $407.9M | $1.2B | ||
| Q2 24 | $344.1M | $2.0B | ||
| Q1 24 | $333.3M | $1.7B |
总债务ENSRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $802.0M | — |
股东权益ENSRVTY
| Q4 25 | $1.9B | $7.3B | ||
| Q3 25 | $1.9B | $7.4B | ||
| Q2 25 | $1.9B | $7.6B | ||
| Q1 25 | $1.9B | $7.6B | ||
| Q4 24 | $1.8B | $7.7B | ||
| Q3 24 | $1.8B | $7.9B | ||
| Q2 24 | $1.8B | $7.9B | ||
| Q1 24 | $1.8B | $7.8B |
总资产ENSRVTY
| Q4 25 | $4.0B | $12.2B | ||
| Q3 25 | $4.1B | $12.1B | ||
| Q2 25 | $4.1B | $12.4B | ||
| Q1 25 | $4.0B | $12.4B | ||
| Q4 24 | $4.0B | $12.4B | ||
| Q3 24 | $4.0B | $12.8B | ||
| Q2 24 | $3.6B | $13.4B | ||
| Q1 24 | $3.5B | $13.4B |
负债/权益比ENSRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.57× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.46× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $184.6M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $171.3M | $161.8M |
| 自由现金流率自由现金流/营收 | 18.6% | 21.0% |
| 资本支出强度资本支出/营收 | 1.4% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.04× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $441.3M | $509.4M |
8季度趋势，按日历期对齐
经营现金流ENSRVTY
| Q4 25 | $184.6M | $182.0M | ||
| Q3 25 | $218.0M | $138.5M | ||
| Q2 25 | $968.0K | $134.3M | ||
| Q1 25 | $135.2M | $128.2M | ||
| Q4 24 | $81.1M | $174.2M | ||
| Q3 24 | $33.6M | $147.9M | ||
| Q2 24 | $10.4M | $158.6M | ||
| Q1 24 | — | $147.6M |
自由现金流ENSRVTY
| Q4 25 | $171.3M | $161.8M | ||
| Q3 25 | $197.1M | $120.0M | ||
| Q2 25 | $-32.1M | $115.5M | ||
| Q1 25 | $104.9M | $112.2M | ||
| Q4 24 | $56.8M | $149.8M | ||
| Q3 24 | $3.3M | $125.6M | ||
| Q2 24 | $-25.7M | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率ENSRVTY
| Q4 25 | 18.6% | 21.0% | ||
| Q3 25 | 20.7% | 17.2% | ||
| Q2 25 | -3.6% | 16.0% | ||
| Q1 25 | 10.8% | 16.9% | ||
| Q4 24 | 6.3% | 20.5% | ||
| Q3 24 | 0.4% | 18.4% | ||
| Q2 24 | -3.0% | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度ENSRVTY
| Q4 25 | 1.4% | 2.6% | ||
| Q3 25 | 2.2% | 2.6% | ||
| Q2 25 | 3.7% | 2.6% | ||
| Q1 25 | 3.1% | 2.4% | ||
| Q4 24 | 2.7% | 3.4% | ||
| Q3 24 | 3.4% | 3.3% | ||
| Q2 24 | 4.2% | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率ENSRVTY
| Q4 25 | 2.04× | 1.85× | ||
| Q3 25 | 3.19× | 2.97× | ||
| Q2 25 | 0.02× | 2.49× | ||
| Q1 25 | 1.40× | 3.03× | ||
| Q4 24 | 0.71× | 1.84× | ||
| Q3 24 | 0.41× | 1.57× | ||
| Q2 24 | 0.15× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ENS
| Energy Systems | $399.5M | 43% |
| Motive Power | $352.0M | 38% |
| Services | $92.6M | 10% |
| Transferred Over Time | $38.2M | 4% |
| Other | $36.8M | 4% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
